Research progress of targeted CAF strategy in PDAC immunotherapy
DOI:
CSTR:
Author:
Affiliation:

1.Medical College of Yanan University;2.Laboratory Animal Center, the Air Force Medical University

Clc Number:

Fund Project:

Special research project on military experimental animals(SYDW_KY[2021]14)

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    【】 Pancreatic ductal adenocarcinoma (PDAC) is a common type of pancreatic cancer, which is insidious, rapidly development and highly malignant. Traditional treatment strategy are not effective for PDAC due to its rich extracellular matrix (ECM). Cancer associated fibroblasts (CAF) are the most important component of ECM. It can interact with other immune components in the tumor microenvironment (TME) by secreting a large number of effector molecules to form immunosuppressive TME, which could allow cancer cells to evade immune system surveillance, promote tumor growth, invasion and metastasis, induce ECM remodeling and drug resistance. This review provided a summary of the research progress on the application of targeted CAF in PDAC immunotherapy. It focus on exploring research strategies that promote the transition of TME from an immunosuppressive state to an immune activated state through depleting CAF, inhibiting effector molecules secreted by CAF, reprogramming CAF, and limiting CAF-induced ECM remodeling. The aim of this review is expected to produce more effective therapeutic strategies and provide new methods for the immunotherapy of PDAC

    Reference
    Related
    Cited by
Get Citation
Related Videos

Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:June 20,2024
  • Revised:August 14,2024
  • Adopted:October 30,2024
  • Online:
  • Published:
Article QR Code